The advice “use champix, quit smoking” may still be good after researchers from the University of Bristol explored possible links between the use of Champix and psychiatric problems. There have been reports that the drug has caused some users to suffer from depression, and in extreme cases even contemplate suicide.
Years back when the drug first became available, health officials in Canada and other areas started to receive reports that Champix was linked to behavioural change problems such as depression, disturbing dreams, and aggression. The problem with these symptoms in this scenario is that they could also be linked to smoking cessation in general.
For example a heavy smoker who stops smoking is likely to be tetchy, grumpy, and volatile; in fact they are likely to exhibit many uncharacteristic negative behaviours.
However, the Bristol study found “no strong scientific evidence” that the use of Champix increases the likelihood of misery or antisocial behaviour, compared with other smoking cessation aids.
Assessing the potential risk from Champix was conducted by comparing it other medications used to help people quit. Users of lozenges gum, patches, inhalers, and Zyban were included in the study, and the sample group was not small- 80,600 18 to 95 year old men and women were involved.
There were reports of adverse effects across the board and Champix didn’t come out as any better or worse in terms of side-effects than the other options.
The findings are publicly available from the British Medical Journal, but the study came with the following advice, it does rule out a link between Champix and behavioural problems, but there is a link between it and its ability to help some people quit smoking.
|Weekly consumption of oily fish rich in ... The essential omega-3 fatty acid abundant in oily fish ...|